Treatment outcomes of post-operative radiotherapy in poorly differentiated and anaplastic thyroid cancer patients at the National Cancer Hospital
Main Article Content
Abstract
Poorly differentiated (PDTC) and anaplastic thyroid cancer (ATC) are rare, accounting for less than 20% of thyroid cancer cases. For high-risk cases, treatment typically involves surgery, with radiation therapy and chemotherapy added as needed. This case serie report includes 16 patients with PDTC or ATC who underwent surgery and radiation therapy, with or without chemotherapy, at theNational Cancer Hospital from January 2018 to December 2023. The study shows that the average age was 67.4 ± 11.2 years. The 3D radiation therapy technique was predominantly selected, at 87.5%, with post-operative radiation doses ranging from 60 - 70Gy depending on the risk level. Common radiation therapy complications included dermatitis, esophagitis, and neck fibrosis. The overall 5-year survival rate was 11.7%. Factors associated with overall survival (OS) and event-free survival (EFS) included histological type, age, surgical margin status, and tumor capsular invasion.
Article Details
Keywords
Poorly Differentiated and Anaplastic Thyroid Cancer, Radiotherapy, Total Thyroidectomy
References
2. Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope. 2004;114(3):393-402. doi:10.1097/00005537-200403000-00001.
3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660.
4. Ibrahimpasic T, Ghossein R, Shah JP, et al. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects. Thyroid. 2019;29(3):311-321. doi:10.1089/thy. 2018.0509.
5. Cancer Statistics Review, 1975-2014 - SEER Statistics. SEER. Accessed July 24, 2024. https://seer.cancer.gov/archive/csr/1975_2014/index.html.
6. Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330-1335. doi:10.1002/cncr.20936.
7. Tong J, Ruan M, Jin Y, et al. Poorly differentiated thyroid carcinoma: a clinician’s perspective. Eur Thyroid J. 2022;11(2):e220021. doi:10.1530/ETJ-22-0021.
8. National Comprehensive Cancer Network. NCCN Guidelines for Thyroid Carcinoma. Accessed July 27, 2024. https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.
9. Lin B, Ma H, Ma M, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res. 2019;11(9):5888-5896.
10. Zivaljevic V, Tausanovic K, Paunovic I, et al. Age as a Prognostic Factor in Anaplastic Thyroid Cancer. Int J Endocrinol. 2014;2014:240513. doi:10.1155/2014/240513.
11. Kong N, Xu Q, Zhang Z, et al. Age Influences the Prognosis of Anaplastic Thyroid Cancer Patients. Front Endocrinol. 2021;12. doi:10.3389/fendo.2021.704596.
12. Hannallah J, Rose J, Guerrero MA. Comprehensive Literature Review: Recent Advances in Diagnosing and Managing Patients with Poorly Differentiated Thyroid Carcinoma. Int J Endocrinol. 2013;2013:317487. doi:10.1155/2013/317487.
13. Park JW, Choi SH, Yoon HI, et al. Treatment outcomes of radiotherapy for anaplastic thyroid cancer. Radiat Oncol J. 2018;36(2):103-113. doi:10.3857/roj.2018.00045.
14. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17-48. doi:10.3322/caac.21763.
15. Wan Z, Wang B, Yao J, et al. Predictive factors and clinicopathological characteristics of outcome in poorly differentiated thyroid carcinoma: a single-institution study. Front Oncol. 2023;13:1102936. doi:10.3389/fonc.2023.1102936.
16. Alhejaily AMG, AlHuzaim O, Alwelaie Y. Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (Review). Mol Clin Oncol. 2023;19(6):99. doi:10.3892/mco.2023.2695.